Truist analyst Richard Newitter lowered the firm’s price target on iRhythm (IRTC) to $200 from $215 but keeps a Buy rating on the shares. The company delivered Q4 revenue as preannounced as the beat was fueled by another strong ZioAT quarter and progress with innovative channel partners, the analyst tells investors in a research note. The firm adds however that peers have seen some multiple compresson, which underlies the slight multiple and price target reduction.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm price target lowered to $184 from $211 at Goldman Sachs
- iRhythm should be bought on subpoena weakness, says William Blair
- iRhythm says received civil investigative demand from DOJ in December
- iRhythm price target lowered to $215 from $240 at JPMorgan
- iRhythm price target lowered to $200 from $220 at Baird